Learn from international recommendations and experiences of countries that have successfully implemented monoclonal antibody prophylaxis for prevention of RSV infection

Abstract Respiratory syncytial virus (RSV)-mediated bronchiolitis causes a significant global health burden. Despite this, for several years, the only approved agent for RSV prophylaxis was the anti-RSV monoclonal antibody Palivizumab, reserved for a small population of infants at high risk of devel...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Manti, Eugenio Baraldi
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Italian Journal of Pediatrics
Subjects:
Online Access:https://doi.org/10.1186/s13052-025-01844-9
Tags: Add Tag
No Tags, Be the first to tag this record!